Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Jariyapongskul, Amporn ^a   Areebambud, Chonticha ^a   Suksamrarn, Sunit ^a   Mekseepralard, Chantana ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA MANGOSTIN; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MALONALDEHYDE; MANGOSTEEN EXTRACT; PLANT EXTRACT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; MANGOSTIN; TUMOR NECROSIS FACTOR; VASCULOTROPIN A; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ANTIGLYCATION ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EYE BLOOD FLOW; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERFUSION; RAT; RETINA BLOOD VESSEL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; COMPLICATION; DIET THERAPY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALIA; RATTUS;

ANIMALS; BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; RATS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHONES;

EID: 84928561973     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/785826     Document Type: Article

References (62)

1. M. J. Fowler, "Microvascular and macrovascular complications of diabetes, " Clinical Diabetes, vol. 26, no. 2, pp. 77-82, 2008.
2. M. Konig, E. M. Lamos, S. A. Stein, and S. N. Davis, "An insight into the recent diabetes trials: what is the best approach to preventmacrovascular and microvascular complications?" Current Diabetes Reviews, vol. 9, no. 5, pp. 371-381, 2013.
3. H. Ahsan, "Diabetic retinopathy-Biomolecules and multiple pathophysiology, " Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 9, no. 1, pp. 51-54, 2015.
4. J. M. Tarr, K. Kaul, M. Chopra, E. M. Kohner, and R. Chibber, "Pathophysiology of diabetic retinopathy, " ISRN Ophthalmology, vol. 2013, Article ID 343560, 13 pages, 2013.
5. Y. Wu, L. Tang, and B. Chen, "Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives, " OxidativeMedicine and Cellular Longevity, vol. 2014, Article ID752387, 12 pages, 2014.
6. A. K. H. Cheung, M. K. L. Fung, A. C. Y. Lo et al. , "Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice, " Diabetes, vol. 54, no. 11, pp. 3119-3125, 2005.
7. E. Bonnardel-Phu, J.-L. Wautier, A. M. Schmidt, C. Avila, and E. Vicaut, "Acutemodulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo, " Diabetes, vol. 48, no. 10, pp. 2052-2058, 1999.
8. N. D. Evcimen and G. L. King, "The role of protein kinase C activation and the vascular complications of diabetes, " Pharmacological Research, vol. 55, no. 6, pp. 498-510, 2007.
9. U. Rajamani and M. F. Essop, "Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis, " The American Journal of Physiology-Cell Physiology, vol. 299, no. 1, pp. C139-C147, 2010.
10. S.-I. Yamagishi, K. Nakamura, and T. Imaizumi, "Advanced glycation end products (AGEs) and diabetic vascular complications, " Current Diabetes Reviews, vol. 1, no. 1, pp. 93-106, 2005.
11. D. Chawla, S. Bansal, B. D. Banerjee, S. V. Madhu, O. P. Kalra, and A. K. Tripathi, "Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications, "Microvascular Research, vol. 95, pp. 1-6, 2014.
12. G. R. Barile and A. M. Schmidt, "RAGE and its ligands in retinal disease, " Current Molecular Medicine, vol. 7, no. 8, pp. 758-765, 2007.
13. A. Bierhaus, P. M. Humpert, M. Morcos et al. , "Understanding RAGE, the receptor for advanced glycation end products, " Journal of Molecular Medicine, vol. 83, no. 11, pp. 876-886, 2005.
14. T. C. B. Moore, J. E. Moore, Y. Kaji et al. , "The role of advanced glycation end products in retinal microvascular leukostasis, " Investigative Ophthalmology and Visual Science, vol. 44, no. 10, pp. 4457-4464, 2003.
15. T. Soulis, M. E. Cooper, S. Sastra et al. , "Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats, " Diabetologia, vol. 40, no. 10, pp. 1141-1151, 1997.
16. R. Bucala, K. J. Tracey, and A. Cerami, "Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes, " Journal of Clinical Investigation, vol. 87, no. 2, pp. 432-438, 1991.
17. J. Pedraza-Chaverri, N. Cárdenas-Rodŕ?guez, M. Orozco-Ibarra, and J. M. Pérez-Rojas, "Medicinal properties of mangosteen (Garciniamangostana), " Food and Chemical Toxicology, vol. 46, no. 10, pp. 3227-3239, 2008.
18. P. Williams, M. Ongsakul, J. Proudfoot, K. Croft, and L. Beilin, "Mangostin inhibits the oxidative modification of human low density lipoprotein, " Free Radical Research, vol. 23, no. 2, pp. 175-184, 1995.
19. W. Mahabusarakam, J. Proudfoot, W. Taylor, and K. Croft, "Inhibition of lipoprotein oxidation by prenylated xanthones derived from mangostin, " Free Radical Research, vol. 33, no. 5, pp. 643-659, 2000.
20. M. Buelna-Chontal, F. Correa, S. Hernández-Reséndiz, C. Zazueta, and J. Pedraza-Chaverri, "Protective effect of-mangostin on cardiac reperfusion damage by attenuation of oxidative stress, " Journal of Medicinal Food, vol. 14, no. 11, pp. 1370-1374, 2011.
21. K. Nakatani, M. Atsumi, T. Arakawa et al. , "Inhibitions of histamine release and prostaglandin E2 synthesis by mangosteen, aThai medicinal plant, " Biological and Pharmaceutical Bulletin, vol. 25, no. 9, pp. 1137-1141, 2002.
22. L.-G. Chen, L.-L. Yang, and C.-C. Wang, "Anti-inflammatory activity of mangostins from Garcinia mangostana, " Food and Chemical Toxicology, vol. 46, no. 2, pp. 688-693, 2008.
23. C. E. Riva, "Basic principles of laser Doppler flowmetry and application to the ocular circulation, " InternationalOphthalmology, vol. 23, no. 4-6, pp. 183-189, 2001.
24. Q. Xu, T. Qaum, and A. P. Adamis, "Sensitive blood-retinal barrier breakdown quantitation using Evans blue, " Investigative Ophthalmology and Visual Science, vol. 42, no. 3, pp. 789-794, 2001.
25. M. J. Reed, K. Meszaros, L. J. Entes et al. , "A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat, " Metabolism: Clinical and Experimental, vol. 49, no. 11, pp. 1390-1394, 2000.
26. S. Suksamrarn, O. Komutiban, P. Ratananukul, N. Chimnoi, N. Lartpornmatulee, and A. Suksamrarn, "Cytotoxic prenylated xanthones from the young fruit of Garcinia mangostana, " Chemical and Pharmaceutical Bulletin, vol. 54, no. 3, pp. 301-305, 2006.
27. A. Chaivisuthangkura, Y. Malaikaew, A. Chaovanalikit et al. , "Prenylated xanthone composition of Garcinia mangostana (Mangosteen) fruit hull, " Chromatographia, vol. 69, no. 3-4, pp. 315-318, 2009.
28. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, " Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
29. M. Zhang, X. Y. Lv, J. Li, Z. G. Xu, and L. Chen, "The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model, " Experimental Diabetes Research, vol. 2008, Article ID 704045, 9 pages, 2008.
30. A. D. Mooradian, "Dyslipidemia in type 2 diabetes mellitus, " Nature Clinical Practice Endocrinology and Metabolism, vol. 5, no. 3, pp. 150-159, 2009.
31. M. Kurniawati, C. Mahdi, and A. Aulanni'am, "The effect of juicemangosteen rind (Garcinia mangostana L. ) to blood sugar levels and histological of pancreatic rats with the induction of streptozotocin, " The Journal of Pure and Applied Chemistry Research, vol. 3, no. 1, pp. 1-6, 2014.
32. T. M. Curtis, T. A. Gardiner, and A. W. Stitt, "Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?" Eye, vol. 23, no. 7, pp. 1496-1508, 2009.
33. J. Cai and M. Boulton, "The pathogenesis of diabetic retinopathy: old concepts and newquestions, " Eye, vol. 16, no. 3, pp. 242-260, 2002.
34. T. Nagaoka, E. Sato, A. Takahashi, H. Yokota, K. Sogawa, and A. Yoshida, "Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser doppler velocimetry study, " Investigative Ophthalmology and Visual Science, vol. 51, no. 12, pp. 6729-6734, 2010.
35. D. Deng, T. Evans, K. Mukherjee, D. Downey, and S. Chakrabarti, "Diabetes-induced vascular dysfunction in the retina: role of endothelins, " Diabetologia, vol. 42, no. 10, pp. 1228-1234, 1999.
36. C. Takagi, S.-E. Bursell, Y.-W. Lin et al. , "Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1, " Investigative Ophthalmology and Visual Science, vol. 37, no. 12, pp. 2504-2518, 1996.
37. T. Nagaoka and A. Yoshida, "Relationship between retinal blood flow and renal function in patients with type 2 diabetes and chronic kidney disease, " Diabetes Care, vol. 36, no. 4, pp. 957-961, 2013.
38. L. Schmetterer and M. Wolzt, "Ocular blood flowand associated functional deviations in diabetic retinopathy, " Diabetologia, vol. 42, no. 4, pp. 387-405, 1999.
39. T. Nishikawa, D. Edelstein, X. L. Du et al. , "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, " Nature, vol. 404, no. 6779, pp. 787-790, 2000.
40. K. K. Griendling and G. A. FitzGerald, "Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS, " Circulation, vol. 108, no. 16, pp. 1912-1916, 2003.
41. M. Kalani, "The importance of endothelin-1 for microvascular dysfunction in diabetes, "VascularHealth and RiskManagement, vol. 4, no. 5, pp. 1061-1068, 2008.
42. A. M. Joussen, V. Poulaki, W. Qin et al. , "Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo, " American Journal of Pathology, vol. 160, no. 2, pp. 501-509, 2002.
43. K. Miyamoto, S. Khosrof, S.-E. Bursell et al. , "Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 19, pp. 10836-10841, 1999.
44. A. Jariyapongskul, T. Rungjaroen, N. Kasetsuwan, S. Patumraj, J. Seki, and H. Niimi, "Long-term effects of oral vitamin C supplementation on the endothelial dysfunction in the iris microvessels of diabetic rats, " Microvascular Research, vol. 74, no. 1, pp. 32-38, 2007.
45. L. M. Reyes-Fermń, S. González-Reyes, N. G. Tarco-Álvarez, M. Hernández-Nava, M. Orozco-Ibarra, and J. Pedraza-Chaverri, "Neuroprotective effect of-mangostin and curcumin against iodoacetate-induced cell death, " Nutritional Neuroscience, vol. 15, no. 5, pp. 34-41, 2012.
46. P. D. Sampath and K. Vijayaraghavan, "Cardioprotective effect of-mangostin, a xanthone derivative from mangosteen on tissue defense system against isoproterenol-inducedmyocardial infarction in rats, " Journal of Biochemical andMolecular Toxicology, vol. 21, no. 6, pp. 336-339, 2007.
47. M. Al-Shabrawey and S. Smith, "Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers, "The EPMA Journal, vol. 1, no. 1, pp. 56-72, 2010.
48. I. G. Obrosova, L. Fathallah, and D. A. Greene, "Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-lipoic acid, " European Journal of Pharmacology, vol. 398, no. 1, pp. 139-146, 2000.
49. B. Márquez-Valadez, R. Lugo-Huitrón, V. Valdivia-Cerda et al. , "The natural xanthone-mangostin reduces oxidative damage in rat brain tissue, " Nutritional Neuroscience, vol. 12, no. 1, pp. 35-42, 2009.
50. A. Pollreisz, B. I. Hudson, J. S. Chang et al. , "Receptor for advanced glycation endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells, " Atherosclerosis, vol. 212, no. 2, pp. 451-456, 2010.
51. S. Umadevi, V. Gopi, and E. Vellaichamy, "Inhibitory effect of gallic acid on advanced glycation end products induced upregulation of inflammatory cytokines and matrix proteins in H9C2 (2-1) cells, " Cardiovascular Toxicology, vol. 13, no. 4, pp. 396-405, 2013.
52. A. K. Mohamed, A. Bierhaus, S. Schiekofer, H. Tritschler, R. Ziegler, and P. P. Nawroth, "The role of oxidative stress and NF-B activation in late diabetic complications, " BioFactors, vol. 10, no. 2-3, pp. 157-167, 1999.
53. X. Gao, S. Belmadani, A. Picchi et al. , "Tumor necrosis factoralpha induces endothelial dysfunction in Lepr mice, " Circulation, vol. 115, no. 2, pp. 245-254, 2007.
54. N. S. Chandel, W. C. Trzyna, D. S. McClintock, and P. T. Schumacker, "Role of oxidants in NF-B activation and TNF-gene transcription induced by hypoxia and endotoxin, " The Journal of Immunology, vol. 165, no. 2, pp. 1013-1021, 2000.
55. C. A. Aveleira, C.-M. Lin, S. F. Abcouwer, A. F. Ambrósio, and D. A. Antonetti, "TNF-signals through PKC/NF-B to alter the tight junction complex and increase retinal endothelial cell permeability, " Diabetes, vol. 59, no. 11, pp. 2872-2882, 2010.
56. S.-I. Yamagishi, K. Nakamura, T. Matsui et al. , "Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression, " The Journal of Biological Chemistry, vol. 281, no. 29, pp. 20213-20220, 2006.
57. H. P. Hammes, S. Martin, K. Federlin, K. Geisen, and M. Brownlee, "Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11555-11558, 1991.
58. H. W. van Dijk, F. D. Verbraak, P. H. Kok et al. , "Early neurodegeneration in the retina of type 2 diabetic patients, " Investigative Ophthalmology & Visual Science, vol. 53, no. 6, pp. 2715-2719, 2012.
59. N. Ashton, "The blood-retinal barrier and vaso-glial relationships in retinal disease. , " Transactions of the Ophthalmological Societies of the United Kingdom, vol. 85, pp. 199-230, 1965.
60. J. Cunha-Vaz, J. R. Faria de Abreu, and A. J. Campos, "Early breakdown of the blood retinal barrier in diabetes, " British Journal of Ophthalmology, vol. 59, no. 11, pp. 649-656, 1975.
61. S. Waltman, T. Krupin, S. Hanish, C. Oestrich, and B. Becker, "Alteration of the blood retinal barrier in experimental diabetes mellitus, " Archives of Ophthalmology, vol. 96, no. 5, pp. 878-879, 1978.
62. C. L. Lobo, R. C. Bernardes, J. P. Figueira, J. R. Faria De Abreu, and J. G. Cunha-Vaz, "Three-year follow-up study of bloodretinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy, " Archives of Ophthalmology, vol. 122, no. 2, pp. 211-217, 2004.